Document is current
Any future updates will be listed below
-
Authors
Muntjewerff, Elke M. https://orcid.org/0000-0002-2281-9776
Epremidze, Dali
Nezhyva, Mariya
Kal, Satadeepa
Rohm, Theresa V.
Tang, Kechun
Singh, Kailash
Espes, Daniel
Jati, Suborno
Bootsma, Marleen https://orcid.org/0009-0004-7778-2212
Mannaa, Atef Mahmoud
Ikebuchi, Hiromi
Nilsson, Anna M.
Rajasekaran, Mahadevan
Andrén, Per E. https://orcid.org/0000-0002-4062-7743
Jansson, Erik T. https://orcid.org/0000-0002-0675-3412
Mahata, Sushil K. https://orcid.org/0000-0002-9154-0787
Christoffersson, Gustaf https://orcid.org/0000-0002-9640-9702
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2018-02314, 2023-02900)
Svenska Sällskapet för Medicinsk Forskning
Barndiabetesfonden
Diabetesfonden
ZonMw (452021310)
U.S. Department of Health & Human Services | National Institutes of Health (R21 AG072487-01, R21 AG080246-01, R21 AG078635-01A1)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_200177)
Larry L. Hillblom Foundation (2023-D-012-FEL)
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 27 October 2025
First Online: 26 November 2025
Competing interests
: The authors declare the following competing interests: A.M.N. and P.E.A. are cofounders of Tag-On AB, and S.K.M. is the founder of CgA Therapeuticals, Inc. and co-founder of Siraj Therapeutics, Inc. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
